JPS604184A - Pyrazoloindazole derivative - Google Patents

Pyrazoloindazole derivative

Info

Publication number
JPS604184A
JPS604184A JP11190383A JP11190383A JPS604184A JP S604184 A JPS604184 A JP S604184A JP 11190383 A JP11190383 A JP 11190383A JP 11190383 A JP11190383 A JP 11190383A JP S604184 A JPS604184 A JP S604184A
Authority
JP
Japan
Prior art keywords
compound
formula
methyl
bromide
reacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP11190383A
Other languages
Japanese (ja)
Inventor
Yasuo Fujimura
保夫 藤村
Isao Matsunaga
功 松永
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority to JP11190383A priority Critical patent/JPS604184A/en
Publication of JPS604184A publication Critical patent/JPS604184A/en
Pending legal-status Critical Current

Links

Abstract

NEW MATERIAL:The compound of formula I (R1 is H or methyl; R2 is H, methyl or phenyl). EXAMPLE:2-Bromo-7-methyl-9-phenyl-2, 3-dihydro-1H-pyrazolo[ 1,2-a ]-indazolium bromide. USE:A bronchodilator. PREPARATION:The compound of formula I is obtained by the thermal cyclization of the compound of formula II. The starting compound of formula II can be prepared easily by reacting the compound of formula III with alkyl bromide, and adding bromine to the reaction product. The compound of formula I can be converted to the compound of formula IV by reacting with NaHCO3 in an aqueous solution. A compound of formula IV wherein R3 is CH3 is prepared directly by reacting the compound of formula III with 3-chloro-2-methyl-1-propene, adding bromine to the reaction product, and thermally cyclizing the addition product.

Description

【発明の詳細な説明】 本発明は次の一般式(,1)及び(II)(式中R1は
水素原子又はメチル基を、R2は水素原子、メチル基又
はフェニル基を、 R3は水素原子又はメチル基を意味
する)で表わされるピラゾロインダゾール誘導体に関す
る。
Detailed Description of the Invention The present invention is based on the following general formulas (,1) and (II) (where R1 is a hydrogen atom or a methyl group, R2 is a hydrogen atom, a methyl group, or a phenyl group, and R3 is a hydrogen atom) or methyl group).

式(1)の本発明の化合物は、例えば次の方法により製
造させる。即ち、次の一般式Cu1l)CH,CH−C
H,Br 8「 (式中R1,R2は前記の意味を有する)で表わされる
化合物を加熱、閉環せしめることにより製造される。な
お、化合物(II)は、一般式(IV)で表わ(式中R
1y R2は前記の意味を有する)にアリルブロマイド
を反応させた後、臭素を付加させることにより容易に得
られる。
The compound of the present invention of formula (1) is produced, for example, by the following method. That is, the following general formula Cu1l)CH,CH-C
It is produced by heating and ring-closing a compound represented by H, Br 8" (wherein R1 and R2 have the above-mentioned meanings). Compound (II) is represented by general formula (IV) ( In the formula R
1y R2 has the above-mentioned meaning) by reacting with allyl bromide and then adding bromine.

式(If)の化合物は、式〔I〕の化合物を水溶液中、
炭酸水素ナトリウムを反応させることにより得られる。
The compound of formula (If) is obtained by preparing the compound of formula [I] in an aqueous solution.
Obtained by reacting sodium hydrogen carbonate.

なお、式(II)においてR3=OH3のものは式CI
V)の化合物に3−クロロ−2〜メチル−1−プリペン
を反応させ、臭素を付加させた後加熱、閉環さ5−メチ
ル−3−フェニルインダゾール32.62、アリルブロ
マイド18.9 f 、テトラブチルアンモニウムブ四
マイト3fをベンゼン20〇−及び25%水酸化ナトリ
ウム水溶液120dに加え60℃、30分攪拌する。ベ
ンゼン層を分取後、水洗、乾燥し減圧濃縮する。残渣を
四塩化炭素300ゴにとかし、氷冷下口塩化炭素501
1Llにとかした臭素25fを滴下する。滴下後室温で
10分攪拌し、11ホルムを加え下に沈んだ油状物を溶
かす。有機層を水洗、乾燥後、減圧濃縮する。残渣をメ
チルエチルケントン200mにとかし、加熱還流15時
間行い、析出物を沖過すると、2−ブロム−7−メチル
−9−フェニル−2,3−ジヒド0− IH−ピラゾロ
(1,2−a)インダゾリウムブロマイド34.9 f
得られる。これを水から再結晶すると、分解点183℃
を示す。
In addition, in formula (II), the one where R3=OH3 is represented by the formula CI
The compound of V) was reacted with 3-chloro-2-methyl-1-prepene, bromine was added thereto, and the ring was closed by heating. Add 3f of butylammonium butymite to 200d of benzene and 120d of 25% aqueous sodium hydroxide solution and stir at 60°C for 30 minutes. After separating the benzene layer, it is washed with water, dried and concentrated under reduced pressure. Dissolve the residue in 300 g of carbon tetrachloride, cool with ice and cool with 501 g of carbon chloride.
25f of bromine dissolved in 1 L is added dropwise. After the dropwise addition, the mixture was stirred at room temperature for 10 minutes, and 11-form was added to dissolve the oily substance that had sunk to the bottom. The organic layer is washed with water, dried, and concentrated under reduced pressure. The residue was dissolved in 200 m of methyl ethyl kentone, heated under reflux for 15 hours, and the precipitate was filtered off to give 2-bromo-7-methyl-9-phenyl-2,3-dihydro-IH-pyrazolo(1,2-a ) indazolium bromide 34.9 f
can get. When this is recrystallized from water, the decomposition point is 183℃
shows.

元素分析 017 )!ts N2 Br5t として
CHN 計算値(至) 50.03 3.95 6.86実測値
(至) 50.04 3.97 6.85実施例2゜ 実施例1の方法に準じて、インダゾールより2−ブロム
−2,3−ジヒドロ−IH−ピラゾロ〔1,2−a)イ
ンダゾリウムプ四マイトを得た。エタノール−エーテル
より再結晶すると分解点181〜2℃を示す。
Elemental analysis 017)! CHN as ts N2 Br5t Calculated value (to) 50.03 3.95 6.86 Actual value (to) 50.04 3.97 6.85 Example 2゜According to the method of Example 1, 2- from indazole Bromo-2,3-dihydro-IH-pyrazolo[1,2-a) indazolium tetramite was obtained. Recrystallization from ethanol-ether shows a decomposition point of 181-2°C.

元素分析 010H1ON2Br2としてOHN 計算値に) 37.77 3.17 8.81実測値(
2) 37J0 3.14 8.65実施例3゜ 実施例1の方法に準じて、3−メチルインダゾールより
2−ブシムー9−メチルー2.3−ジヒドロ−IH−ピ
ラゾロ(1,2−a)インダゾリウムプロマイドを得た
。水−アセトンより再結晶すると分解点202℃を示し
た。
Elemental analysis OHN calculated value as 010H1ON2Br2) 37.77 3.17 8.81 Actual value (
2) 37J0 3.14 8.65 Example 3゜According to the method of Example 1, 2-busymo-9-methyl-2,3-dihydro-IH-pyrazolo(1,2-a)in was prepared from 3-methylindazole. Dazolium bromide was obtained. Recrystallization from water-acetone showed a decomposition point of 202°C.

元素分析 011H12N2Br2 ・−!−H20と
して0 HN 計算値(至) 38,74 3.84 8.21実測値
(至) 38,47 3.59 8.02実施例4゜ 実施例1で得られた2−ブロム−7−メチル−9−フェ
ニル−2,3−ジヒドロ−IH−ピラゾp(1,2−a
)インダゾリウムブロマイドLOPを水250m/に加
え、さらに炭酸水素ナトリウム2゜52を加え、60℃
、4時間加熱、攪拌する。溶媒を100罰まで濃縮し、
HP−20(300WLl)のカラムクロマトに付し、
目的物を分取、濃縮し、残渣をアセトンに懸濁、濾過し
、7−メチル−9−フェニル−9H−ビラゾt’(1,
2−a)インダゾリウムプロマイド5.1fを得る。水
より再結晶すると分解点238℃を示す。
Elemental analysis 011H12N2Br2 ・-! -H20 as 0 HN Calculated value (to) 38,74 3.84 8.21 Actual value (to) 38,47 3.59 8.02 Example 4゜2-Brom-7- obtained in Example 1 Methyl-9-phenyl-2,3-dihydro-IH-pyrazo p(1,2-a
) Add indazolium bromide LOP to 250 m of water, add 2°52 of sodium bicarbonate, and heat at 60°C.
, heat and stir for 4 hours. Concentrate the solvent to 100%,
Subjected to HP-20 (300WLl) column chromatography,
The target product was collected and concentrated, and the residue was suspended in acetone and filtered to obtain 7-methyl-9-phenyl-9H-virazot' (1,
2-a) Obtain indazolium bromide 5.1f. When recrystallized from water, it shows a decomposition point of 238°C.

元素分析 017H15N2BrとしてOHN 計算値(至) 62.40 4.62 8.56実測値
(転) 62.31 4.64 8.60実施例5゜ 実施例2で得られた、2〜ブロム−2,3−ジヒドロ−
IH−ピラゾロ[:1,2−a]インダゾリウムプロマ
イドより、実施例4の方法に準じて、9H−ピラゾロ(
1,2−a)インダゾリウムプロマイドを得た。水−ア
セトンより再結晶すると融点222〜3℃を示す。
Elemental analysis OHN as 017H15N2Br Calculated value (total) 62.40 4.62 8.56 Actual value (total) 62.31 4.64 8.60 Example 5゜2~Brom-2 obtained in Example 2 ,3-dihydro-
From IH-pyrazolo[:1,2-a]indazolium bromide, 9H-pyrazolo(
1,2-a) Indazolium bromide was obtained. When recrystallized from water-acetone, it shows a melting point of 222-3°C.

元素分析 010 R9N2 BrとしてOHN 計算値(1) 50.66 3.83 11.82実測
値% 50.54 3.79 11.60実施例6゜ 実施例3で得られた、2−ブロム−9−メチル−2,3
−ジヒドロ−IH−ピラゾロ(1,2−a)インダゾリ
ウムブロマイドより実施例4の方法に準じて9−メチル
−9H−ピラゾロCI、2−a:1インダゾリウムブロ
マイドを得た。エタノール−エーテルより再結晶すると
m p 205〜6℃を示す。
Elemental analysis 010 R9N2 OHN as Br Calculated value (1) 50.66 3.83 11.82 Actual value % 50.54 3.79 11.60 Example 6° 2-brome-9 obtained in Example 3 -methyl-2,3
9-Methyl-9H-pyrazolo CI, 2-a:1 indazolium bromide was obtained from -dihydro-IH-pyrazolo(1,2-a) indazolium bromide according to the method of Example 4. Recrystallization from ethanol-ether shows m p of 205-6°C.

元素分析 011 I(11N2 BrとしてOHN 計算値(至) 52,61 4.42 11.16実測
値(至) 52.71 4.39 11.01実施例7
゜ 5−メチル−3−フェニルインダゾール32.61、テ
トラブチルアンモニウムブロマイド32゜3−り四ロー
2−メチルーエープ田ベン16Fをベンゼン250ゴ及
び25%水酸化ナトリウム水溶液70−に加え3時間加
熱還流し、ベンゼン層を水洗、乾燥、濃縮する。残渣を
四塩化炭素250dにとかし、臭素251を水冷下部下
する。室温30分攪拌後、水洗、乾燥、濃縮l残渣をメ
チルエチルケン)200mA’にとかし、加熱還流30
時間行う。析出物を濾過し、スフ−ジメチル−9−フェ
ニル−9H〜ビラゾt’(1,2−a)インダゾリウム
ブロマイド8.11得る。水より再結晶すると分解点2
70℃を示す。
Elemental analysis 011 I (OHN as 11N2 Br Calculated value (to) 52,61 4.42 11.16 Actual value (to) 52.71 4.39 11.01 Example 7
5-Methyl-3-phenylindazole 32.61, tetrabutylammonium bromide 32.3-di-2-methyl-Apetaben 16F were added to 250 grams of benzene and 70 grams of a 25% aqueous sodium hydroxide solution and heated under reflux for 3 hours. , wash the benzene layer with water, dry and concentrate. The residue was dissolved in 250 d of carbon tetrachloride, and 251 d of bromine was added under water cooling. After stirring at room temperature for 30 minutes, the residue was washed with water, dried, and concentrated.
Do time. The precipitate was filtered to obtain 8.11 of sufu-dimethyl-9-phenyl-9H-virazot'(1,2-a) indazolium bromide. Decomposition point 2 when recrystallized from water
Indicates 70°C.

元素分析 018H17N2 Brとして0 、HN 計算値(1) 63.35 5.02 8.21実測値
(A 63.14 5.04 8.11出願人 中外製
薬株式会社
Elemental analysis 018H17N2 0 as Br, HN Calculated value (1) 63.35 5.02 8.21 Actual value (A 63.14 5.04 8.11 Applicant Chugai Pharmaceutical Co., Ltd.

Claims (1)

【特許請求の範囲】 り一般式 (式中B1は水素原子又はメチル基を、R2は水素原子
、メチル基又はフェニル基を意味する)で表わされるピ
ラゾロインダゾール誘導体。 2、一般式 (式中R1は水素原子又はメチル基を、R2は水素原子
、メチル基又はフェニル基を、R3は水素原子又はメチ
ル基を意味する)で表わされるピラゾロインダゾール誘
導体。
[Scope of Claims] A pyrazoloindazole derivative represented by the general formula (wherein B1 represents a hydrogen atom or a methyl group, and R2 represents a hydrogen atom, a methyl group, or a phenyl group). 2. A pyrazoloindazole derivative represented by the general formula (wherein R1 means a hydrogen atom or a methyl group, R2 means a hydrogen atom, methyl group or phenyl group, and R3 means a hydrogen atom or a methyl group).
JP11190383A 1983-06-23 1983-06-23 Pyrazoloindazole derivative Pending JPS604184A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP11190383A JPS604184A (en) 1983-06-23 1983-06-23 Pyrazoloindazole derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11190383A JPS604184A (en) 1983-06-23 1983-06-23 Pyrazoloindazole derivative

Publications (1)

Publication Number Publication Date
JPS604184A true JPS604184A (en) 1985-01-10

Family

ID=14573011

Family Applications (1)

Application Number Title Priority Date Filing Date
JP11190383A Pending JPS604184A (en) 1983-06-23 1983-06-23 Pyrazoloindazole derivative

Country Status (1)

Country Link
JP (1) JPS604184A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053268A3 (en) * 2000-01-18 2001-12-27 Agouron Pharma Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
EP2065383A1 (en) 2003-11-19 2009-06-03 Signal Pharmaceuticals, Inc. Indazole compounds and methods of use thereof as protein kinase inhibitors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053268A3 (en) * 2000-01-18 2001-12-27 Agouron Pharma Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
EP2065383A1 (en) 2003-11-19 2009-06-03 Signal Pharmaceuticals, Inc. Indazole compounds and methods of use thereof as protein kinase inhibitors

Similar Documents

Publication Publication Date Title
US4113731A (en) Fused isoquinoline derivatives
EP0510436B1 (en) Process for preparation of asymetric isoindoline pigments
JP3892036B2 (en) Process for producing 2- (substituted benzoyl) -1,3-cyclohexanediones
JPH01160957A (en) Bis(indoryl)ethylene
JPS604184A (en) Pyrazoloindazole derivative
US5177209A (en) Process for preparation of asymmetric isoindoline pigments
IL33920A (en) Process for the manufacture of oximino-dithiolanes
JPH0312058B2 (en)
EP0047674B1 (en) Novel process for preparing isoindolin derivatives
US4188325A (en) Isatin process and products
US4186132A (en) Isatin products
JPS5927343B2 (en) Synthesis method of 3-aminoisoxazoles
US4267388A (en) Process for producing ethynylbenzenes
JP4434747B2 (en) Method for producing 1,2,3-triazole compound
JPH01160958A (en) Bis(indolyl)ethylene aldehydes
JP2937387B2 (en) Process for producing 5-substituted 2-amino-3-cyanopyrazines
JP3376481B2 (en) Method for producing hexahydropyridazine
JPH0480029B2 (en)
Shvaika et al. Researches on oxazoles: II. Halogen derivatives of phenyloxazoles
JPS5846514B2 (en) Method for producing 3-phenylindole derivative
BE552215A (en)
JPS6249271B2 (en)
JPH0138119B2 (en)
JP2002212457A (en) Naphthalimide compound and blue fluorescent pigment
JPS6242975A (en) Production of heterocyclic compound